Synergistic anti-pneumocystis carinii effects of erythromycin and sulfisoxazole

Walter T. Hughes, John T. Killmar

Research output: Contribution to journalArticle

Abstract

Pneumocystis carinii pneumonitis was effectively prevented in 90% of immunosuppressed rats by the administration of 100 mg of erythromycin and 300 mg/kg/day of sulfisoxazole. All of the untreated control and erythromycintreated animals developed the infection and 80% of rats given sulfisoxazole alone had the pneumonitis. A similar pattern of response occurred when the drugs were used therapeutically for rats with established P. carinii pneumonitis. The erythromycin and sulfisoxazole ratio of 1:3 was the most effective of several dose combinations tested. The established safety record from three decades of clinical use of this drug combination plus the broad spectrum of coverage for other causes of diffuse pneumonitis such as Chlamydia, Mycoplasma, and Legionella warrant further study of erythromycin-sulfisoxazole in AIDS patients.

Original languageEnglish (US)
Pages (from-to)532-537
Number of pages6
JournalJournal of Acquired Immune Deficiency Syndromes
Volume4
Issue number5
StatePublished - 1991
Externally publishedYes

Fingerprint

Sulfisoxazole
Pneumocystis carinii
Erythromycin
Pneumonia
Legionella
Chlamydia
Mycoplasma
Drug Combinations
Acquired Immunodeficiency Syndrome
Safety
Infection
Pharmaceutical Preparations

Keywords

  • Erythromycin
  • Pneumocystis carinii
  • Pneumonitis
  • Sulfisoxazole

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)
  • Immunology and Allergy
  • Virology

Cite this

Synergistic anti-pneumocystis carinii effects of erythromycin and sulfisoxazole. / Hughes, Walter T.; Killmar, John T.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 4, No. 5, 1991, p. 532-537.

Research output: Contribution to journalArticle

@article{d821020f130145e3a103b793ae802114,
title = "Synergistic anti-pneumocystis carinii effects of erythromycin and sulfisoxazole",
abstract = "Pneumocystis carinii pneumonitis was effectively prevented in 90{\%} of immunosuppressed rats by the administration of 100 mg of erythromycin and 300 mg/kg/day of sulfisoxazole. All of the untreated control and erythromycintreated animals developed the infection and 80{\%} of rats given sulfisoxazole alone had the pneumonitis. A similar pattern of response occurred when the drugs were used therapeutically for rats with established P. carinii pneumonitis. The erythromycin and sulfisoxazole ratio of 1:3 was the most effective of several dose combinations tested. The established safety record from three decades of clinical use of this drug combination plus the broad spectrum of coverage for other causes of diffuse pneumonitis such as Chlamydia, Mycoplasma, and Legionella warrant further study of erythromycin-sulfisoxazole in AIDS patients.",
keywords = "Erythromycin, Pneumocystis carinii, Pneumonitis, Sulfisoxazole",
author = "Hughes, {Walter T.} and Killmar, {John T.}",
year = "1991",
language = "English (US)",
volume = "4",
pages = "532--537",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Synergistic anti-pneumocystis carinii effects of erythromycin and sulfisoxazole

AU - Hughes, Walter T.

AU - Killmar, John T.

PY - 1991

Y1 - 1991

N2 - Pneumocystis carinii pneumonitis was effectively prevented in 90% of immunosuppressed rats by the administration of 100 mg of erythromycin and 300 mg/kg/day of sulfisoxazole. All of the untreated control and erythromycintreated animals developed the infection and 80% of rats given sulfisoxazole alone had the pneumonitis. A similar pattern of response occurred when the drugs were used therapeutically for rats with established P. carinii pneumonitis. The erythromycin and sulfisoxazole ratio of 1:3 was the most effective of several dose combinations tested. The established safety record from three decades of clinical use of this drug combination plus the broad spectrum of coverage for other causes of diffuse pneumonitis such as Chlamydia, Mycoplasma, and Legionella warrant further study of erythromycin-sulfisoxazole in AIDS patients.

AB - Pneumocystis carinii pneumonitis was effectively prevented in 90% of immunosuppressed rats by the administration of 100 mg of erythromycin and 300 mg/kg/day of sulfisoxazole. All of the untreated control and erythromycintreated animals developed the infection and 80% of rats given sulfisoxazole alone had the pneumonitis. A similar pattern of response occurred when the drugs were used therapeutically for rats with established P. carinii pneumonitis. The erythromycin and sulfisoxazole ratio of 1:3 was the most effective of several dose combinations tested. The established safety record from three decades of clinical use of this drug combination plus the broad spectrum of coverage for other causes of diffuse pneumonitis such as Chlamydia, Mycoplasma, and Legionella warrant further study of erythromycin-sulfisoxazole in AIDS patients.

KW - Erythromycin

KW - Pneumocystis carinii

KW - Pneumonitis

KW - Sulfisoxazole

UR - http://www.scopus.com/inward/record.url?scp=0025780332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025780332&partnerID=8YFLogxK

M3 - Article

C2 - 2016690

AN - SCOPUS:0025780332

VL - 4

SP - 532

EP - 537

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 5

ER -